In 2023, experts decided against adding obesity drugs to the World Health Organisation's essential medicines list.

Viking is developing what might be a game-changing medication in the segment.

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

The U.S. State Department has approved the potential sale of F-16 training and sustainment, along with related equipment, for ...

The U.S. Food and Drug Administration is asking some of its recently fired staff responsible for critically important funding ...

The top sustainable finance executive at HSBC's asset management division is leaving the firm, HSBC said on Friday, the ...

Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease ...

More than a billion people now have obesity worldwide, according to the WHO, and around 70% of them live in low and ...

Health Secretary Robert F. Kennedy Jr. will testify before the U.S. Senate's health committee on May 14, the panel said on ...

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Canadian oil producer Imperial Oil posted a rise in first-quarter profit on Friday, driven primarily by stronger margins in ...